Effects of mosapride, a 5-hydroxytryptamine 4 receptor agonist, on electrical activity of the small intestine and cecum in horses.

This research studied the effect of varied doses of mosapride, a drug, on the motility of the small intestine and cecum in horses. It found that mosapride stimulates motility in these organs, suggesting potential usefulness in treating horses with gastrointestinal dysfunction.

Introduction and Methods

• The study aimed to understand the impact of mosapride on the intestines’ electrical activity in horses. Mosapride is an agonist for the 5-hydroxytryptamine 4 receptor.
• The researchers experimented with different doses of the drug and analyzed the effect to find the dosage for optimal response.
• The subject pool consisted of six healthy adult Thoroughbreds. The horses’ intestinal and cecum electrical activity was recorded before and after the administration of mosapride.
• Mosapride was dissolved in water and given orally through a nasogastric tube in doses of 0.5, 1, 1.5 and 2 mg/kg.
• The mean amplitude of electrical activity post three hours of drug administration was calculated and expressed as a percentage of the mean amplitude before drug administration.

Results

• The results indicated an increase in the electrical activity in the intestines and cecum. This indicated that mosapride stimulated increased motility in these organs.
• This percentage increase was found to be dose-dependent, with higher doses resulting in greater effects.
• Specifically, doses of 1, 1.5 and 2 mg/kg caused significant increases in the small intestine, while doses of 1.5 and 2 mg/kg effected significant increases in the cecum.

Conclusion

• The analysis documented that mosapride promotes motility in the small intestines and cecum of horses, with the optimal dosage being 1.5 to 2 mg/kg when administered orally.
• The results of the study highlight the potential benefits of mosapride for treating gastrointestinal tract dysfunction in horses.